New Study On Prevention Of Transfer Of HIV

New Study On Prevention Of Transfer Of HIV.
An antiviral stupefy may serve screen injection drug users from HIV infection, a recent study finds. The study of more than 2400 injection poison users recruited at 17 drug treatment clinics in Thailand found that continuously tablets of tenofovir reduced the risk of HIV infection by nearly 49 percent, compared to non-functioning placebo pills switzerland. One pundit said an intervention to help shield injection soporific users from HIV - the virus that causes AIDS - is much needed.

And "This is an superior study that opens up an additional way out for preventing HIV in a hard-to-reach population," said Dr Joseph McGowan, medical overseer at the Center for AIDS Research and Treatment at North Shore University Hospital in Manhasset, NY. He eminent that "HIV infections proceed to develop at high rates, with over 2,5 million worldwide and 50000 unfamiliar infections in the US each year bhai bhen sex store sunne wale mp. This is ignoring widespread knowledge about HIV infection and the way it is spread, through unprotected f__king and sharing needles for injecting drugs".

The participants included in the budding study were followed for an average of four years. During that time, 17 of the more than 1200 patients taking tenofovir became infected with HIV, compared with 33 of an proportionate tons of patients taking a placebo, according to the inspect published online June 12, 2013 in The Lancet. Further analyses of the results showed that the sheltering effect of tenofovir was highest surrounded by those who most closely followed the drug's prescribed regimen.

In this group, the jeopardy of HIV infection was reduced by more than 70 percent, said swotting leaders Dr Kachit Choopanya and Dr Michael Martin, outstanding of clinical research for the Thailand Ministry of Public Health-US Centers for Disease Control and Prevention Collaboration. Prior experiment with has shown that hampering use of antiviral drugs cuts the gamble of sexual transmission of HIV in both heterosexual couples and men who have coupling with men, and also reduces mother-to-child transmission of HIV.

But this is the elementary study to show that this approach might also be effective among injection sedative users. Worldwide, injection drug use is believed to cause one in 10 callow HIV infections. But rates of infection associated with injection tranquillizer use are far higher in some areas of the world, such as eastern Europe and chief Asia.

In these regions, up to 80 percent of unknown HIV infections are caused by injection drug use. According to McGowan, tenofovir is no "silver bullet" that would, on its own, remove the jeopardize of HIV infection for drug abusers. But it could be a pitch ingredient in reducing the odds.

So "Adoption of this strategy, not as a stand-alone, but in conjunction with needle exchange, counseling, opiate substitution, group underpinning and mental health therapy may enable us to get up ahead of this expanding epidemic". He added that the participants in the study were also provided with what's known as "directly observed therapy," where the hallucinogen is administered under the inspection of a health care worker.

Services like this, along with monthly HIV testing and condom distribution, might not take place in "real life" healing situations so outcomes might not be as good as in this clinical trial. Another whiz agreed that adherence to tenofovir group therapy is key to success in store. Tenofovir "accumulates slowly in the body, making the event for adherence - which is strongly associated with the efficacy of the drug," said Victoria Richards, aide-de-camp professor of medical sciences at the Frank H Netter MD School of Medicine at Quinnipiac University, in Hamden, Conn.